Kyntra Bio, Inc.

United States

Last price 4.65 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 18.83M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United ...